

November 13, 2014



OncoSec Medical To Present at 2014 Stifel Healthcare Conference

SAN DIEGO-- OncoSec Medical Inc. (OTCQB: [ONCS](#)), a company developing DNA-based intratumoral cancer immunotherapies, will present at the 2014 Stifel Healthcare Conference, taking place November 18-19 at the New York Palace Hotel in New York City.

Punit Dhillon, President and CEO, will present a corporate overview of the Company on Wednesday, November 19, at 4:45 PM EST. At the time of the presentation, a live webcast will be available via the following link:

<http://www.veracast.com/webcasts/stifel/healthcare2014/69214592.cfm>

OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available in the "Events" section of the OncoSec web page at <http://www.oncosec.com>.

About Stifel Healthcare Conference 2014

The Stifel Healthcare Conference will attract top institutional investors and leading companies in the healthcare sector. The Conference is designed to provide institutional investors with high-level access to senior management and industry experts, showcase dynamic emerging companies, and investigate critical trends that are driving our economy. For more information, please visit: <http://www.stifel.com>

About OncoSec Medical

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from

the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Relations:

OncoSec Medical Inc.

Jordyn Kopin, 855-662-6732

investors@oncosec.com

or

Public Relations:

Dian Griesel, Int'l.

Laura Radocaj, 212-825-3210

lradocaj@dgi-comm.com

Source: OncoSec Medical Inc.